Skip to main navigationSkip to main content
The University of Southampton
Southampton Health Technology Assessments CentreNews

New SHTAC report on the clinical effectiveness and cost-effectiveness of topotecan for small cell lung cancer: a systematic review and economic evaluation

Published: 16 April 2011
New SHTAC report

A systematic review and economic evaluation of topotecan for small cell lung cancer is now available.

A systematic review and economic evaluation of the clinical and cost-effectiveness of the drug topotecan as a second-line treatment for small cell lung cancer has been published in the Health Technology Assessment monograph series. The project was conducted by SHTAC and informed the NICE appraisal of this drug for lung cancer. The study found that, as a second-line treatment for patients with relapsed small cell lung cancer, topotecan is better than best supportive care in terms of improved survival. Treatment with oral topotecan may be cost-effective compared with best supportive care.  

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×